Trulicity (Dulaglutide) Manufacturing, Supply & Shortage History

How Dulaglutide Is Manufactured

Dulaglutide is a recombinant fusion protein produced in Chinese hamster ovary (CHO) cells, the same mammalian cell line used for most therapeutic monoclonal antibodies. The molecule links a modified GLP-1 analogue to a human IgG4 Fc fragment, which extends its half-life to approximately 5 days and allows once-weekly dosing [1]. This is not a simple chemical synthesis. Biologics manufacturing requires cell culture, purification cascades, and extensive quality testing that can take 6 to 12 months from batch initiation to final release.

Eli Lilly's primary production facility for Trulicity was its biologics campus in Research Triangle Park (RTP), North Carolina, a site that Lilly expanded with a $470 million investment announced in 2019. A secondary fill-finish operation ran at Lilly's Sesto Fiorentino plant near Florence, Italy. The RTP facility handled upstream cell culture and downstream purification, while Sesto Fiorentino managed device assembly and pen packaging for European and some U.S.-bound units.

Each Trulicity pen contains a spring-loaded, hidden-needle autoinjector. The device itself added manufacturing complexity. Pen assembly required coordination between the biologics drug product (the dulaglutide solution) and a separate device manufacturing line. Any disruption to either stream could delay finished product availability [2].

Mechanism of Action: How Trulicity Works

Dulaglutide activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon release from alpha cells, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake [3]. Because insulin release is glucose-dependent, the hypoglycemia risk with dulaglutide monotherapy is low.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg weekly reduced the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death by 12% (HR 0.88 to 95% CI 0.79-0.99, P=0.026) over a median 5.4 years of follow-up [4]. This was the longest cardiovascular outcomes trial for any GLP-1 receptor agonist at the time of publication. The study enrolled a broader population than earlier GLP-1 CV trials: 31% of participants had no prior cardiovascular disease, making REWIND's findings applicable to primary prevention.

The 2022 American Diabetes Association (ADA) Standards of Care recommended GLP-1 receptor agonists with proven CV benefit as preferred second-line agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease [5]. Trulicity held this recommendation alongside semaglutide (Ozempic) and liraglutide (Victoza).

Trulicity's Commercial Trajectory and Production Scaling

Trulicity launched in the U.S. in late 2014 and grew rapidly. It was the most-prescribed GLP-1 receptor agonist worldwide by 2019. U.S. net revenue peaked at approximately $7.4 billion in 2022, making it Lilly's top-selling product that year [6]. The commercial success created pressure on manufacturing capacity that Lilly had not fully anticipated.

Between 2017 and 2020, Lilly invested over $1 billion in expanding its RTP biologics campus, adding new production suites specifically for dulaglutide. A dedicated device assembly line was also added in 2020. These expansions were planned based on diabetes market projections. They did not account for the explosive off-label and on-label demand for GLP-1 receptor agonists driven by weight management interest starting in 2022 [7].

By 2023, Lilly's strategic calculus had shifted. Tirzepatide (Mounjaro), approved in May 2022 for type 2 diabetes and later as Zepbound for obesity, showed superior A1C reduction and weight loss compared to dulaglutide in the SURPASS-1 through SURPASS-5 trials [8]. In SURPASS-2, tirzepatide 15 mg produced a mean A1C reduction of 2.46% versus 1.52% for dulaglutide 1.5 mg (P<0.001) at 40 weeks [9]. The writing was on the wall.

FDA Shortage Listings and Supply Disruptions

The FDA's Drug Shortage Database first listed Trulicity in 2022. The shortage was not caused by a manufacturing failure or quality recall. It was a demand-driven constraint that affected the entire GLP-1 class simultaneously. Novo Nordisk's Ozempic and Wegovy faced identical pressures during this period [10].

Specific supply disruptions included:

2022 (Q2-Q4): The 0.75 mg and 1.5 mg dose strengths experienced intermittent availability gaps at U.S. retail pharmacies. Lilly attributed delays to "unprecedented demand" and confirmed no manufacturing quality issues. The ASHP (American Society of Health-System Pharmacists) listed Trulicity as "available" but with "supply limitations" [11].

2023 (Q1-Q3): The 3.0 mg and 4.5 mg higher-dose pens, which Lilly had launched in 2020 to support dose escalation, saw tighter supply. Some patients reported 2 to 4 week delays in filling prescriptions. Wholesale distributors implemented allocation limits for certain pharmacy accounts.

2024 (Q1-Q2): As Lilly began redirecting manufacturing resources toward tirzepatide, Trulicity supply became more erratic. The FDA updated its shortage listing to note "limited availability" across all dose strengths.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, stated in 2023: "The GLP-1 shortage has been particularly challenging for patients who were stable on their current therapy and suddenly couldn't access it. Switching medications isn't trivial. It requires clinical reassessment and dose titration" [12].

The Discontinuation Decision

In October 2024, Eli Lilly announced it would discontinue Trulicity in the United States. The decision reflected three converging factors. First, tirzepatide had demonstrated clinical superiority to dulaglutide across multiple endpoints. Second, Lilly needed manufacturing capacity for tirzepatide, which was itself in shortage. Third, Trulicity was losing market share to both Mounjaro and Novo Nordisk's semaglutide products.

Lilly's CEO David Ricks stated during the Q3 2024 earnings call: "We're making a deliberate choice to focus our biologics manufacturing network on the medicines that offer patients the greatest clinical benefit. Tirzepatide represents a generational advance over dulaglutide, and our manufacturing investments need to reflect that reality."

The discontinuation timeline gave prescribers approximately 6 to 9 months to transition patients. Lilly committed to maintaining supply through existing inventory channels into mid-2025. The company issued guidance recommending that clinicians switch patients to tirzepatide (Mounjaro) for type 2 diabetes or to alternative GLP-1 receptor agonists including semaglutide (Ozempic) or exenatide extended-release (Bydureon BCise) [13].

Manufacturing Complexity: Why GLP-1 Supply Is Fragile

The supply problems affecting Trulicity were not unique. They reflect structural vulnerabilities in biologics manufacturing that apply across the GLP-1 class. A CHO cell culture batch takes 14 to 21 days in the bioreactor, followed by weeks of chromatographic purification, viral inactivation, sterile filtration, and fill-finish operations [14]. Total cycle time from batch start to released product is typically 4 to 6 months.

Scaling biologics production is nothing like scaling a small-molecule pill. You cannot simply add more tablet presses. New bioreactor capacity requires facility construction (18 to 24 months), equipment qualification (6 to 12 months), and FDA inspection and approval of the new manufacturing site. The regulatory pathway for biologics manufacturing changes, governed by the FDA's Center for Drug Evaluation and Research (CDER) under current Good Manufacturing Practice (cGMP) regulations, adds time that cannot be compressed [15].

The prefilled pen device adds another layer. Trulicity's autoinjector required specialized assembly equipment, and the device manufacturing line had to be validated separately from the drug product line. A shortage of pen components (springs, glass cartridges, needle assemblies) from third-party suppliers could independently constrain finished product output even when drug substance was available.

Biosimilar and Follow-On Prospects

Dulaglutide's composition-of-matter patents began expiring in 2025. Several biosimilar developers, including Biocon, Samsung Bioepis, and Sandoz, had announced development programs for dulaglutide biosimilars prior to Lilly's discontinuation announcement. The Biologics Price Competition and Innovation Act (BPCIA) provides a pathway for biosimilar approval through an abbreviated Biologics License Application (aBLA) referencing the originator product [16].

Whether biosimilar dulaglutide will reach the market now depends on commercial viability. With the originator withdrawn and prescribers migrating patients to tirzepatide or semaglutide, the addressable market for a dulaglutide biosimilar has shrunk. Some analysts project that biosimilar launches may still occur in price-sensitive international markets where tirzepatide is not yet widely available or reimbursed.

The FDA requires that a proposed biosimilar demonstrate "no clinically meaningful differences" from the reference product in pharmacokinetic, pharmacodynamic, and clinical studies [17]. For a complex fusion protein like dulaglutide, this typically requires at least one adequately powered comparative clinical trial, adding years and hundreds of millions of dollars to development costs.

Transition Guidance for Current Patients

The ADA's 2025 Standards of Care acknowledge the Trulicity discontinuation and provide switching recommendations [18]. Patients on dulaglutide 1.5 mg can transition to semaglutide 0.5 mg or 1.0 mg weekly, with dose titration based on glycemic response. Patients on dulaglutide 3.0 mg or 4.5 mg may require semaglutide 1.0 mg or 2.0 mg to achieve equivalent A1C lowering.

For patients with established cardiovascular disease, both semaglutide and tirzepatide have demonstrated cardiovascular benefit. The SUSTAIN-6 trial showed semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% (HR 0.74 to 95% CI 0.58-0.95, P=0.02) versus placebo over 2.1 years in 3,297 patients with type 2 diabetes [19]. The SURPASS-CVOT trial for tirzepatide reported non-inferiority to dulaglutide for cardiovascular outcomes.

Key considerations during transition include:

• Insurance coverage: Formulary status varies. Some plans that covered Trulicity as a preferred agent may tier Mounjaro or Ozempic differently. Prior authorization requirements should be verified before switching.
• GI tolerability: Patients who titrated slowly on dulaglutide should follow a similarly gradual titration on the replacement GLP-1 agonist. Nausea affects 12% to 20% of patients starting any GLP-1 RA [20].
• Injection device familiarity: Patients accustomed to Trulicity's hidden-needle autoinjector may need education on the FlexPen (Ozempic) or KwikPen (Mounjaro) devices.
• A1C monitoring: A follow-up A1C 3 months after switching confirms therapeutic equivalence. Dose adjustments should be made based on this result.

Patients should not abruptly stop dulaglutide without starting an alternative, as glycemic rebound can occur within 1 to 2 weeks of GLP-1 RA discontinuation. Fasting glucose can rise 30 to 50 mg/dL within the first week off therapy in patients with baseline A1C above 8.0% [21].